Fortrustar completes angel round financing, focusing on product, supply chain, and channels
methuselah
Medical Nutrition Product R&D, Production, and Sales
In March 2026, Fortrustar officially announced the completion of its angel round financing. The round was incubated and exclusively led by Hongsheng Capital, with deep participation and follow-on investment from Methunutrition, a leading company in medical nutrition. In the same month, Fortrustar announced a strategic partnership with KE-99Lacto, a benchmark brand in evidence-based nutrition. The two parties will engage in multi-level collaboration in the field of infant and toddler nutritional intervention, jointly advancing the professionalization and standardization of child nutrition and health in China.
The successful completion of this financing and the associated series of collaborations not only injects solid capital momentum into Fortrustar's development, but also marks the company's official entry into a systematic and scaled phase of deployment in the field of child nutrition. It also reflects the recognition of Fortrustar by capital and industry partners, as well as their attention to the development potential of the child nutritional intervention sector.
In recent years, with the widespread dissemination of science-based parenting concepts, the infant and toddler health market has been undergoing a structural upgrade. Infant and toddler food and nutrition services are gradually transitioning from "basic supply" to "professional precision," with higher demands placed on product safety, formula scientific validity, and brand professionalism. At the same time, nutritional intervention, as one of the core pathways for child health management, has become increasingly important, serving as a key lever for safeguarding children's growth and development.
Since its establishment in October 2025, Fortrustar has been committed to building an evidence-based child nutritional intervention system. Leveraging clinical research and experimental data, the company bridges the gap between scientific validity and practical application, guiding child health management toward a standardized pathway that is verifiable, actionable, and implementable.
Fortrustar's core research and development team hails from top-tier research institutions such as Harvard University, Shanghai Jiao Tong University, and Fudan University. Its core management team comes from leading maternal and child industry companies such as Mead Johnson Nutrition, Nutricia, and GenSci, possessing a composite background in both healthcare and consumer sectors. With years of deep industry experience, the team can precisely capture the intersection of clinical needs and everyday consumer scenarios, providing a solid foundation for product development and market implementation.
The funds from this angel round financing will be primarily directed toward three core areas: first, improving the child nutritional intervention product system, focusing on clinical needs to drive product iteration; second, optimizing supply chain capabilities to ensure product quality and supply stability; and third, strengthening market channel construction to expand product reach. Concurrently, Fortrustar will advance product development and validation based on clinical research and experimental data, ensuring product scientific validity and safety.
